0.63  -0.013 (-1.95%)		04-25 16:00
Open: 0.668 High: 0.668 Volume: 239,146		Pre. Close: 0.6425 Low: 0.6036 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.97	1-year :	1.14
Resists	First :	0.83	Second :	0.97
Pivot price	0.72
Supports	First :	0.6	Second :	0.5
MAs	MA(5) :	0.65	MA(20) :	0.76
	MA(100) :	2.78	MA(250) :	4.39
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	6.4	D(3) :	6.7
RSI	RSI(14): 18.2
52-week	High :	12	Low :	0.6

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ QNRX ] has closed above bottom band by 8.1%. Bollinger Bands are 81.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.67 - 0.67	0.67 - 0.68
Low:	0.59 - 0.6	0.6 - 0.6
Close:	0.62 - 0.63	0.63 - 0.64

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Fri, 15 Mar 2024
Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know - Markets Insider

Wed, 13 Mar 2024
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results - Yahoo Finance

Thu, 07 Mar 2024
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call ... - Yahoo Finance

Tue, 05 Mar 2024
Healthcare Stocks Making Moves Tuesday: BYSI, OCEA, CMAX, CDIO, QNRX, EKSO, ZCMD, SMLR - InvestorsObserver

Tue, 05 Mar 2024
Quoin stock craters 47% on public offering after rallying in prior session (NASDAQ:QNRX) - Seeking Alpha

Tue, 05 Mar 2024
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	4 (M)
Held by Insiders	0.5 (%)
Held by Institutions	2.2 (%)
Shares Short	12 (K)
Shares Short P.Month	13 (K)

EPS	-9.65
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.73
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-44.1 %
Return on Equity (ttm)	-133 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.52
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.07
PEG Ratio	0
Price to Book value	0.1
Price to Sales	0
Price to Cash Flow	-0.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.